Megan L Hames1, Heidi Chen2, Wade Iams3, Jonathan Aston1, Christine M Lovly4, Leora Horn5. 1. Department of Pharmaceutical Sciences, Vanderbilt University Medical Center (VUMC) 1211 Medical Center Drive, Nashville, TN 37232, United States. 2. Department of Cancer Biostatistics, Vanderbilt-Ingram Cancer Center (VICC)/Vanderbilt University Medical Center (VUMC) 2220 Pierce Avenue, 625 Preston Research Building, Nashville, TN 37232, United States. 3. Department of Internal Medicine, 1211 Medical Center Drive, Nashville, TN 37232, United States. 4. Department of Medicine/Division of Hematology-Oncology, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, United States; Department of Cancer Biology, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, United States. 5. Department of Medicine/Division of Hematology-Oncology, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, United States. Electronic address: leora.horn@vanderbilt.edu.
Abstract
OBJECTIVES: KRAS mutations are the most commonly found mutations in patients with non-small cell lung cancer (NSCLC) adenocarcinoma histology. The clinical implications of KRAS mutations in patients with advanced NSCLC are not well defined. We sought to determine if there is a correlation between KRAS mutation status, response to cytotoxic chemotherapy, and survival in patients with metastatic or recurrent NSCLC. MATERIALS AND METHODS: Patients with metastatic or recurrent NSCLC and tumor mutation analyses were analyzed for response to conventional chemotherapy. The presence or absence of tumor mutations was assessed with the SNaPshot assay, which detects >40 somatic mutations in eight genes, including KRAS. ALK fluorescence in-situ hybridization analysis was done separately. Associations between KRAS mutation status and response to chemotherapy and survival were assessed. RESULTS: We identified 80 patients with metastatic or recurrent NSCLC and a KRAS activating mutation, and we compared these patients to 70 patients who were pan negative (no detectable mutation by the SNaPshot assay and ALK negative). Patients with KRAS-mutant advanced NSCLC demonstrated a significantly shorter progression-free survival in response to first line chemotherapy (4.5 months versus 5.7 months, p=0.008) compared to pan-mutation negative patients. Overall survival was also significantly shorter in patients with KRAS-mutant advanced NSCLC compared to patients without KRAS activating mutations (8.8 months versus 13.5 months, p=0.038). CONCLUSIONS: Within this single institution retrospective analysis, patients with advanced NSCLC and a KRAS activating mutation exhibited inferior responses to cytotoxic chemotherapy and decreased survival compared to patients with advanced NSCLC and no KRAS mutation.
OBJECTIVES:KRAS mutations are the most commonly found mutations in patients with non-small cell lung cancer (NSCLC) adenocarcinoma histology. The clinical implications of KRAS mutations in patients with advanced NSCLC are not well defined. We sought to determine if there is a correlation between KRAS mutation status, response to cytotoxic chemotherapy, and survival in patients with metastatic or recurrent NSCLC. MATERIALS AND METHODS:Patients with metastatic or recurrent NSCLC and tumor mutation analyses were analyzed for response to conventional chemotherapy. The presence or absence of tumor mutations was assessed with the SNaPshot assay, which detects >40 somatic mutations in eight genes, including KRAS. ALK fluorescence in-situ hybridization analysis was done separately. Associations between KRAS mutation status and response to chemotherapy and survival were assessed. RESULTS: We identified 80 patients with metastatic or recurrent NSCLC and a KRAS activating mutation, and we compared these patients to 70 patients who were pan negative (no detectable mutation by the SNaPshot assay and ALK negative). Patients with KRAS-mutant advanced NSCLC demonstrated a significantly shorter progression-free survival in response to first line chemotherapy (4.5 months versus 5.7 months, p=0.008) compared to pan-mutation negative patients. Overall survival was also significantly shorter in patients with KRAS-mutant advanced NSCLC compared to patients without KRAS activating mutations (8.8 months versus 13.5 months, p=0.038). CONCLUSIONS: Within this single institution retrospective analysis, patients with advanced NSCLC and a KRAS activating mutation exhibited inferior responses to cytotoxic chemotherapy and decreased survival compared to patients with advanced NSCLC and no KRAS mutation.
Authors: E Rulli; M Marabese; V Torri; G Farina; S Veronese; A Bettini; F Longo; L Moscetti; M Ganzinelli; C Lauricella; E Copreni; R Labianca; O Martelli; S Marsoni; M Broggini; M C Garassino Journal: Ann Oncol Date: 2015-07-24 Impact factor: 32.976
Authors: M Macerelli; C Caramella; L Faivre; B Besse; D Planchard; V Polo; M Ngo Camus; A Celebic; V Koubi-Pick; L Lacroix; J P Pignon; J C Soria Journal: Lung Cancer Date: 2014-01-03 Impact factor: 5.705
Authors: Wouter W Mellema; Anne-Marie C Dingemans; Erik Thunnissen; Peter J F Snijders; Jules Derks; Daniëlle A M Heideman; Robertjan Van Suylen; Egbert F Smit Journal: J Thorac Oncol Date: 2013-09 Impact factor: 15.609
Authors: Christine M Lovly; Kimberly Brown Dahlman; Laurel E Fohn; Zengliu Su; Dora Dias-Santagata; Donna J Hicks; Donald Hucks; Elizabeth Berry; Charles Terry; MarKeesa Duke; Yingjun Su; Tammy Sobolik-Delmaire; Ann Richmond; Mark C Kelley; Cindy L Vnencak-Jones; A John Iafrate; Jeffrey Sosman; William Pao Journal: PLoS One Date: 2012-04-20 Impact factor: 3.240
Authors: B Ricciuti; M Brambilla; A Cortellini; A De Giglio; C Ficorella; A Sidoni; G Bellezza; L Crinò; V Ludovini; S Baglivo; G Metro; R Chiari Journal: Clin Transl Oncol Date: 2019-07-22 Impact factor: 3.405
Authors: Dong Hoon Shin; Ji-Youn Han; Sun Ha Kim; Minyoung Choi; Young-Ki Bae; Chungyong Han; Beom K Choi; Sang Soo Kim Journal: Oncogene Date: 2021-11-06 Impact factor: 9.867
Authors: Anna Biernacka; Peter D Tsongalis; Jason D Peterson; Francine B de Abreu; Candice C Black; Edward J Gutmann; Xiaoying Liu; Laura J Tafe; Christopher I Amos; Gregory J Tsongalis Journal: Cancer Genet Date: 2016-03-18